Search research articles
Contact Us
Filters
Showing results (91-100 of 135) with videos related to
Page
of 14
Sort By:
Pharmacotherapy
|
November 1, 1995
Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan
W D Figg, G E Dukes, H R Lesesne, et al.
Leukemia
|
April 29, 2005
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
S Kumar, N Raje, T Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
M A Rudek, W D Figg, V Dyer, et al.
Cancer Research
|
February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers
E C Kohn, E Reed, G Sarosy, et al.
Journal of Clinical Pharmacology
|
March 1, 1996
Pharmacokinetics of ondansetron in patients with hepatic insufficiency
W D Figg, G E Dukes, J F Pritchard, et al.
The Pharmacogenomics Journal
|
December 30, 2009
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
J F Deeken, T Cormier, D K Price, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response
C J Bowden, W D Figg, N A Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 1999
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer
K S Bauer, W D Figg, J M Hamilton, et al.
Biochemical and Biophysical Research Communications
|
February 1, 2000
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay
E A Kruger, P H Duray, M G Tsokos, et al.
Cancer Chemotherapy and Pharmacology
|
September 28, 1998
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models
E A Sausville, R D Lush, D Headlee, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 135) with videos related to
Sort By:
Page
of 14
Pharmacotherapy
|
November 1, 1995
Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan
W D Figg, G E Dukes, H R Lesesne, et al.
Leukemia
|
April 29, 2005
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
S Kumar, N Raje, T Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2001
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
M A Rudek, W D Figg, V Dyer, et al.
Cancer Research
|
February 1, 1996
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers
E C Kohn, E Reed, G Sarosy, et al.
Journal of Clinical Pharmacology
|
March 1, 1996
Pharmacokinetics of ondansetron in patients with hepatic insufficiency
W D Figg, G E Dukes, J F Pritchard, et al.
The Pharmacogenomics Journal
|
December 30, 2009
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
J F Deeken, T Cormier, D K Price, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response
C J Bowden, W D Figg, N A Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 1999
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer
K S Bauer, W D Figg, J M Hamilton, et al.
Biochemical and Biophysical Research Communications
|
February 1, 2000
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay
E A Kruger, P H Duray, M G Tsokos, et al.
Cancer Chemotherapy and Pharmacology
|
September 28, 1998
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models
E A Sausville, R D Lush, D Headlee, et al.
Page
of 14